Appendix A.
Comparison of baseline characteristics between AMI patients who died within 30 days of admission and those who survived for 30 days subsequent to admission in the EFFECT Baseline and Follow-up samples
| Variable | EFFECT Baseline sample Death within 30 days | p-value | EFFECT Follow-up sample Death within 30 –days | p-value | ||
|---|---|---|---|---|---|---|
| No (N = 8288) | Yes (N = 1010) | No (N = 6206) | Yes (N = 726) | |||
| Age | 68.0 (56.0–77.0) | 80.0 (73.0–86.0) | <.001 | 68.0 (56.0–78.0) | 82.0 (74.0–87.0) | <.001 |
| Female sex | 2837 (34.2%) | 496 (49.1%) | <.001 | 2209 (35.6%) | 354 (48.8%) | <.001 |
| Cardiogenic shock | 50 (0.6%) | 92 (9.1%) | <.001 | 6 (0.1%) | 14 (1.9%) | <.001 |
| Acute congestive heart failure/pulmonary edema | 390 (4.7%) | 136 (13.5%) | <.001 | 369 (5.9%) | 110 (15.2%) | <.001 |
| Systolic blood pressure | 148.0 (129.0–170.0) | 128.5 (106.0–150.0) | <.001 | 144.0 (125.0–165.0) | 123.0 (104.0–146.0) | <.001 |
| Diastolic blood pressure | 83.0 (71.0–96.0) | 72.5 (60.0–88.0) | <.001 | 80.0 (70.0–93.0) | 70.0 (58.0–84.0) | <.001 |
| Heart rate | 80.0 (67.0–96.0) | 90.0 (72.0–111.0) | <.001 | 81.0 (68.0–97.0) | 90.0 (74.0–109.0) | <.001 |
| Respiratory rate | 20.0 (18.0–22.0) | 22.0 (20.0–28.0) | <.001 | 20.0 (18.0–21.0) | 20.0 (18.0–26.0) | <.001 |
| Diabetes | 2094 (25.3%) | 339 (33.6%) | <.001 | 1683 (27.1%) | 249 (34.3%) | <.001 |
| Hypertension | 3793 (45.8%) | 493 (48.8%) | 0.067 | 3599 (58.0%) | 450 (62.0%) | 0.039 |
| Current smoker | 2815 (34.0%) | 195 (19.3%) | <.001 | 1777 (28.6%) | 100 (13.8%) | <.001 |
| Dyslipidemia | 2676 (32.3%) | 183 (18.1%) | <.001 | 2821 (45.5%) | 266 (36.6%) | <.001 |
| Family history of CAD | 2693 (32.5%) | 135 (13.4%) | <.001 | 2096 (33.8%) | 91 (12.5%) | <.001 |
| Cerebrovascular disease/TIA | 761 (9.2%) | 188 (18.6%) | <.001 | 673 (10.8%) | 183 (25.2%) | <.001 |
| Angina | 2715 (32.8%) | 358 (35.4%) | 0.086 | 1823 (29.4%) | 276 (38.0%) | <.001 |
| Cancer | 234 (2.8%) | 51 (5.0%) | <.001 | 94 (1.5%) | 22 (3.0%) | 0.003 |
| Dementia | 239 (2.9%) | 129 (12.8%) | <.001 | 265 (4.3%) | 126 (17.4%) | <.001 |
| Peptic ulcer disease | 459 (5.5%) | 56 (5.5%) | 0.993 | 285 (4.6%) | 62 (8.5%) | <.001 |
| Previous AMI | 1863 (22.5%) | 280 (27.7%) | <.001 | 1430 (23.0%) | 242 (33.3%) | <.001 |
| Asthma | 452 (5.5%) | 62 (6.1%) | 0.368 | 384 (6.2%) | 43 (5.9%) | 0.779 |
| Depression | 571 (6.9%) | 105 (10.4%) | <.001 | 593 (9.6%) | 102 (14.0%) | <.001 |
| Peripheral vascular disease | 593 (7.2%) | 119 (11.8%) | <.001 | 488 (7.9%) | 107 (14.7%) | <.001 |
| Previous revascularization | 770 (9.3%) | 78 (7.7%) | 0.102 | 775 (12.5%) | 81 (11.2%) | 0.302 |
| Congestive heart failure | 326 (3.9%) | 132 (13.1%) | <.001 | 312 (5.0%) | 102 (14.0%) | <.001 |
| Hyperthyroidism | 96 (1.2%) | 20 (2.0%) | 0.026 | 18 (0.3%) | ≤5 (0.1%) | 0.458 |
| Aortic stenosis | 118 (1.4%) | 41 (4.1%) | <.001 | 101 (1.6%) | 37 (5.1%) | <.001 |
| Hemoglobin | 141.0 (129.0–151.0) | 128.0 (114.0–143.0) | <.001 | 141.0 (127.0–152.0) | 125.0 (111.0–138.0) | <.001 |
| White blood count | 9.4 (7.6–11.8) | 11.6 (9.1–15.0) | <.001 | 9.6 (7.7–12.1) | 11.7 (8.9–15.6) | <.001 |
| Sodium | 139.0 (137.0–141.0) | 139.0 (136.0–141.0) | <.001 | 139.0 (137.0–141.0) | 138.0 (135.0–141.0) | <.001 |
| Potassium | 4.0 (3.7–4.4) | 4.2 (3.9–4.7) | <.001 | 4.0 (3.7–4.4) | 4.3 (3.9–4.8) | <.001 |
| Glucose | 7.7 (6.3–10.5) | 9.8 (7.3–14.3) | <.001 | 7.5 (6.3–9.9) | 9.0 (6.8–12.3) | <.001 |
| Urea | 6.3 (5.0–8.2) | 9.3 (6.6–14.4) | <.001 | 6.4 (5.0–8.5) | 10.2 (7.3–15.2) | <.001 |
| Creatinine | 91.0 (77.0–110.0) | 120.0 (92.0–171.0) | <.001 | 92.0 (79.0–113.0) | 127.0 (95.0–181.0) | <.001 |
Note: Continuous variables are reported as median (25th percentile–75th percentile); dichotomous variables are reported as N (%).
The Kruskal–Wallis test and the Chi-squared test were used to compare continuous and categorical baseline characteristics, respectively, between patients who died within 30 days of admission and those who did not in each of the EFFECT Baseline and EFFECT Follow-up samples.